Media Center
Filter by:
April 08, 2024
Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
March 25, 2024
Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
November 12, 2023
Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina
November 07, 2023
Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
August 16, 2023
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
June 05, 2023
Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
May 17, 2023
Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
January 09, 2023
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
December 05, 2022
Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
December 05, 2022
Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM
October 10, 2022
Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase
September 15, 2022
Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium
August 26, 2022